Patents Assigned to Osaka University
  • Publication number: 20240117381
    Abstract: A CRISPR-Cas3 system was successfully established in a eukaryotic cell.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 11, 2024
    Applicant: OSAKA UNIVERSITY
    Inventors: Tomoji MASHIMO, Junji TAKEDA, Hiroyuki MORISAKA, Kazuto YOSHIMI
  • Publication number: 20240117313
    Abstract: A method for producing a three-dimensional tissue construct comprising mature adipocytes, comprising incubating cells comprising at least fat-derived stein cells in the presence of one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
    Type: Application
    Filed: February 15, 2022
    Publication date: April 11, 2024
    Applicants: TOPPAN INC., OSAKA UNIVERSITY, Kyoto Prefectural Public University Corporation
    Inventors: Shiro KITANO, Michiya MATSUSAKI, Fiona LOUIS, Yoshihiro SOWA
  • Publication number: 20240120817
    Abstract: A permanent magnet-type rotary electric machine includes a stator, a first rotor, and a second rotor. The stator includes a stator core, a plurality of stator teeth, a plurality of stator slots, a plurality of stator magnets, and a stator coil. The first rotor is disposed inside the stator core relative to the plurality of stator magnets. The second rotor is disposed inside the stator core relative to a plurality of first pole pieces. The second rotor includes a plurality of second pole pieces. A proportion of the number of the plurality of stator slots to the number of poles of the plurality of second pole pieces of the second rotor is greater than 1.25 and less than 1.5, or greater than 1.5 and less than 3.0.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 11, 2024
    Applicants: Mitsubishi Electric Corporation, OSAKA UNIVERSITY
    Inventors: Haruyuki KOMETANI, Ryoji MIYATAKE, Takuro YAMADA, Kenji TANAKA, Katsuhiro HIRATA, Noboru NIGUCHI, Kazuaki TAKAHARA, Hironori SUZUKI, Takuya ITO
  • Patent number: 11951125
    Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: April 9, 2024
    Assignee: OSAKA UNIVERSITY
    Inventors: Hikaru Kobayashi, Yuki Kobayashi, Ryoichi Imamura, Norio Nonomura
  • Patent number: 11950946
    Abstract: A technique for automating the identifying of a measurement point in cephalometric image analysis is provided. An automatic measurement point recognition method includes a step of detecting, from a cephalometric image 14 acquired from a subject, a plurality of peripheral partial regions 31, 32, 33, 34 for recognizing a target feature point, a step of estimating a candidate position of the feature point in each of the peripheral partial regions 31, 32, 33, 34 by the application of a regression CNN model 10, and a step of determining the position of the feature point in the cephalometric image 14 based on the distribution of the candidate positions estimated. In the step of detecting, for example, the peripheral partial region 32, a classification CNN model 13 trained with a control image 52 is applied.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: April 9, 2024
    Assignee: OSAKA UNIVERSITY
    Inventors: Chihiro Tanikawa, Chonho Lee
  • Patent number: 11939744
    Abstract: A display system includes: an image acquisition unit that acquires each of a first image of a work site imaged by a first camera and a second image of the work site imaged by a second camera; a viewpoint position calculation unit that calculates a viewpoint position of worker; a luminance adjustment unit that adjusts luminance of at least one of the first image and the second image based on the viewpoint position; and a display control unit that combines the first image and the second image having the luminance adjusted and causes a display device to display the combined image.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: March 26, 2024
    Assignees: Komatsu Ltd., Osaka University
    Inventors: Youjirou Ohbatake, Taro Maeda, Masahiro Furukawa, Daisuke Kondo, Masataka Kurokawa
  • Publication number: 20240097547
    Abstract: Provided is a magnetic strain wave gear device that makes it possible to achieve both improvement of the efficiency of assembly work and suppression of decrease in energy conversion efficiency. A magnetic strain wave gear device includes: a stator having a stator core, a stator winding, and a stator magnet; a first rotor; and a second rotor. The second rotor includes a second rotor core provided with a plurality of rotor magnet insertion holes and a plurality of rotor magnets inserted into the plurality of respective rotor magnet insertion holes. The first rotor includes a cylindrical first rotor core and a first rotor end plate. The first rotor end plate has a rotor magnet passage hole through which the rotor magnets can be inserted into the rotor insertion holes from outside in a direction of a rotation shaft.
    Type: Application
    Filed: August 2, 2021
    Publication date: March 21, 2024
    Applicants: Mitsubishi Electric Corporation, OSAKA UNIVERSITY
    Inventors: Yosuke UCHIDA, Ryoji MIYATAKE, Atsushi YAMAMOTO, Haruyuki KOMETANI, Noboru NIGUCHI, Katsuhiro HIRATA, Kazuaki TAKAHARA, Hironori SUZUKI, Takuya ITO
  • Patent number: 11932696
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: March 19, 2024
    Assignees: SHIONOGI & CO., LTD., OSAKA UNIVERSITY
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Patent number: 11933735
    Abstract: An optical detection device is an optical detection device that detects a desired wavelength component included in input light, and includes: a spectrometer including, for instance, a diffraction grating that receives the input light as an input and outputs an alignment of spectra each of which is a duplication of a spectrum of the input light; a second slit array including an array of three or more slits that pass light beams of wavelengths at three or more locations in the alignment of the spectra that are output from the spectrometer; and an imaging element composed of an array of pixels that receive the light beams, having passed through the second slit array, each of the light beams having three or more wavelength components. At least two pitches between slits are different in the array of the three or more slits included in the second slit array.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 19, 2024
    Assignee: OSAKA UNIVERSITY
    Inventor: Tsuyoshi Konishi
  • Publication number: 20240082637
    Abstract: An exercise support apparatus includes an information processing unit that supports a setting of a next exercise menu for improvement to a targeted body, based on prior body motion information on a subject detected by a motion sensor.
    Type: Application
    Filed: December 13, 2021
    Publication date: March 14, 2024
    Applicant: OSAKA UNIVERSITY
    Inventors: Ken NAKATA, Takashi KANAMOTO
  • Publication number: 20240086756
    Abstract: An information processing apparatus determines a combination of a first data qubit and a second data qubit that further reduces the energy represented by an energy equation. The energy equation includes first to third energy terms. The first energy term is used to identify the first data qubit on which a Z error has occurred. The second energy term is used to identify the second data qubit on which an X error has occurred. The third energy term reduces the energy as the number of data qubits each being a third data qubit on which both a Z error and an X error have simultaneously occurred increases. The information processing apparatus determines that a Y error has occurred on the third data qubit.
    Type: Application
    Filed: July 27, 2023
    Publication date: March 14, 2024
    Applicants: Fujitsu Limited, OSAKA UNIVERSITY
    Inventors: Jun FUJISAKI, Hirotaka OSHIMA, Keisuke FUJII
  • Patent number: 11926853
    Abstract: Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: March 12, 2024
    Assignee: The Research Foundation For Microbial Diseases of Osaka University
    Inventors: Daisuke Yokouchi, Akiko Miura, Ryu Okada, Yuzo Yamashita, Yuya Sasaki, Shogo Nishihata
  • Patent number: 11920161
    Abstract: Provided are a cell population substantially consisting of mammalian cells that are positive for cell surface markers CD31 and CD200 and negative for CD45; a cell population substantially consisting of mammalian cells that are positive for cell surface markers CD31, CD157 and CD200 and negative for CD45; a mammalian vascular endothelial stem cell that is positive for the cell surface marker CD31, positive for at least one of CD157 and CD200, and negative for CD45; and a medicament for vascular regeneration, comprising any of the cell populations or the vascular endothelial stem cells as an active ingredient.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: March 5, 2024
    Assignee: Osaka University
    Inventors: Nobuyuki Takakura, Hisamichi Naito, Taku Wakabayashi
  • Patent number: 11922277
    Abstract: A high accuracy information extracting device construction system includes: a feature quantity extraction expression list generating unit for generating a feature quantity extraction expression list; a feature quantity calculating unit for calculating feature quantities of teacher data by means of respective feature quantity extracting expressions; a teacher data supply unit for supplying teacher data; an evaluation value calculating unit for generating information extracting expressions by means of machine learning on the basis of the calculated feature quantities of teacher data and the teacher data, and calculating evaluation values for the respective feature quantity extracting expressions; and a synthesis unit for constructing a high accuracy information extracting device using T weak information extracting parts F(X)t output from the evaluation value calculating unit 15 and confidence levels Ct corresponding thereto.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: March 5, 2024
    Assignee: OSAKA UNIVERSITY
    Inventor: Aya Nakae
  • Publication number: 20240065992
    Abstract: An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression. A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 29, 2024
    Applicants: KINKI UNIVERSITY, YASHIRO CO., LTD., OSAKA UNIVERSITY
    Inventors: Nobuhiro ZAIMA, Hirona KUGO, Motohiro KITANO, Yoshinori HIROTA, Ken-ichi HIRANO
  • Patent number: 11914009
    Abstract: An NMR apparatus includes a depressurizing device for depressurizing an NMR probe, a gas supply device for supplying gas into the NMR probe to thereby pressurize the NMR probe, and a control device. The control device alternately repeats depressurization of the NMR probe, using the depressurizing device, and pressurization of the NMR probe, using the gas supply device. This replaces the gas in the NMR probe.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: February 27, 2024
    Assignees: JEOL Ltd., OSAKA UNIVERSITY
    Inventors: Hiroki Takahashi, Yuki Endo, Toshimichi Fujiwara, Yoh Matsuki
  • Publication number: 20240058365
    Abstract: [Object] It is an object to provide a highly safe and easy-to-administer pharmaceutical preparation for treating epilepsy, pharmaceutical preparation for treating an autism spectrum disorder, and/or pharmaceutical preparation for treating an anxiety disorder. [Solving Means] A topical preparation containing as an active ingredient at least one selected from the group consisting of sirolimus and a sirolimus derivative is a pharmaceutical preparation that is easy to administer, and is highly safe as a therapeutic agent for epilepsy, an autism spectrum disorder, and/or an anxiety disorder. Suitable examples of the active ingredient include sirolimus, everolimus, temsirolimus, ridaforolimus, and zotarolimus.
    Type: Application
    Filed: October 7, 2020
    Publication date: February 22, 2024
    Applicant: OSAKA UNIVERSITY
    Inventor: Mari KANEDA
  • Publication number: 20240060878
    Abstract: An objection is to provide a method for characterizing a molecule delivery particle, the method comprising determining a molar concentration thereof. The method for characterizing a molecule delivery particle, the method comprising subjecting a molecule delivery particle comprising a first particle and a second particle to particle separation with optical measurement to determine an increment in refractive index of each of the first particle and the second particle; and determining a molar concentration of each of the first particle and the second particle based on the increment in refractive index, a molecular weight, and a specific refractive index increment of each of the first particle and the second particle.
    Type: Application
    Filed: March 24, 2022
    Publication date: February 22, 2024
    Applicant: OSAKA UNIVERSITY
    Inventors: Susumu UCHIYAMA, Takahiro MARUNO, Tetsuo TORISU
  • Publication number: 20240063334
    Abstract: Provided is a method for manufacturing a semiconductor nanoparticle, the method includes performing a heat treatment of a first mixture containing a silver (Ag) salt, an alkali metal salt, a salt containing at least one of indium (In) and gallium (Ga), a sulfur source, and an organic solvent. A ratio of the number of atoms of an alkali metal to the total number of atoms of Ag and the alkali metal in the first mixture is greater than 0 and less than 1.
    Type: Application
    Filed: July 25, 2023
    Publication date: February 22, 2024
    Applicants: National University Corporation Tokai National Higher Education and Research System, OSAKA UNIVERSITY, NICHIA CORPORATION
    Inventors: Tsukasa TORIMOTO, Tatsuya KAMEYAMA, Yuki MORI, Hiroki YAMAUCHI, Susumu KUWABATA, Taro UEMATSU, Daisuke OYAMATSU
  • Patent number: 11905308
    Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: February 20, 2024
    Assignee: OSAKA UNIVERSITY
    Inventors: Satoshi Obika, Kosuke Ito, Takaki Habuchi, Masahiko Horiba